glp-1 weight loss drugs news today With FDA approval of Wegovy pill, new era of oral begins GLP-1 weight loss drugs leave

Afternoon fatigue and brain fog

Its a functional disorder affecting your stomach nerves and muscles.

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Read how the new Wegovy pill compares to shots like Ozempic to learn which form might be best for you.

No injections

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D